# Drawray

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/drawray

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.szdrawray.com
- Latest round: Series A (Oct 30, 2025)
- Investors on record: 1

## About

Based in Shenzhen, China, Drawray is a high-tech enterprise specializing in the development and production of advanced in vitro diagnostic (IVD) products, particularly for point-of-care testing (POCT) applications.Drawray, founded in 2019, is dedicated to the field of in vitro diagnostics, focusing on innovative solutions for healthcare. The company operates out of Shenzhen, China. The founder's prior entrepreneurial experience is not documented. As of now, Drawray has completed a single deal, with its most recent funding occurring on October 30, 2025.  In this round, the company raised an undisclosed amount in Series A funding from Shenzhen Capital Real Estate Fund, marking it as a targeted investment.Shenzhen Zhuo Run Biotechnology Co., Ltd. specializes in developing, producing, and selling in vitro diagnostic (IVD) products primarily focused on point-of-care testing (POCT). The company offers a range of diagnostic solutions that include self-contained battery-operated devices, printers, and scanning heads, designed for use in emergency vehicles, clinical departments, and epidemic inspection stations. Notable features of their products include single-use reagent strips with an extended shelf life without the need to open the packaging, as well as advanced magnetic microparticle acridine chemiluminescence technology, which enables accurate and rapid testing. Their product line boasts a diverse array of testing capabilities, including patented assays for liver fibrosis, with results available in as little as 11 minutes. The company serves healthcare institutions and laboratories within the domestic Chinese market as well as international markets, ensuring broad accessibility to their innovative diagnostic solutions.Shenzhen Zhuo Run Biotechnology Co., Ltd. operates through a business model that emphasizes direct sales and partnerships with healthcare providers. Revenue is generated primarily through the sale of its diagnostic devices and related reagents, with a structured pricing model that accommodates bulk purchases for larger institutions while also catering to smaller clinics. The company’s flagship products are designed for high throughput, with the capability to process up to 150 tests per hour, thus appealing to both direct consumers and business-to-business (B2B) clients. The transaction structures typically involve direct sales agreements, where healthcare providers place orders based on their testing needs, ensuring a steady stream of revenue aligned with the demand for diagnostic services. The company's commitment to quality and innovation is reinforced by its multiple certifications, enhancing its credibility and appeal within the market.In October 2025, Drawray completed a Series A funding round from Shenzhen Capital Real Estate Fund, and the proceeds are allocated primarily towards enhancing research and development, production capabilities, and marketing efforts for their in vitro diagnostic products. The company is working on launching new products aimed at expanding its range in the biopharmaceutical sector. Furthermore, Drawray is strategizing to penetrate new international markets, although specific regions have yet to be disclosed.

## Funding rounds

- Series A, Oct 30, 2025 — Shenzhen Capital Real Estate Fund

## Investors

- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A